Recurrent Inflammatory Breast Carcinoma: Prevalence, Patterns of Recurrence, and Therapeutic Approach

  • Juan Alberto Serrano-Olvera
  • Claudia Arce-Salinas
  • David F. Cantu-de Leon
  • Luis Alonso Herrera-Montalvo
  • Jaime G. de la Garza-Salazar


At present, between 80 and 90 % of cases affected by inflammatory breast cancer (IBC) are treated with multimodal therapy. Neoadjuvant chemotherapy (CT) schemes are mainly comprised of anthracyclines and/or taxanes. Recurrent disease has a prevalence of 70 % and the majority of cases are detected prior to 2 years from the end of multimodal therapy; the recurrence of inflammatory carcinoma can manifest at the locoregional, systemic, or central nervous system (CNS) level; these data can be considered on evaluating the therapeutic options of recurrent inflammatory carcinoma. In this chapter, we approach the behavioral characteristics and therapeutic options of recurrent disease in terms of the recurrence patterns identified.


Overall Survival Standard Uptake Value National Cancer Comprehensive Network Locoregional Recurrence Inflammatory Breast Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Globocan. International agency for research on cancer. 2008. Available at: Accesed July 2011.
  2. 2.
    Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Canc Netw. 2011;9:233–41.PubMedGoogle Scholar
  3. 3.
    Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer. Breast Dis. 2005;22:9–23.PubMedGoogle Scholar
  4. 4.
    Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: the disease, the biology and the treatment. CA Cancer J Clin. 2010;60:351–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008;26:786–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Ben Abdallah M, et al. Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol. 2008;19:473–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Hance KW, Anderson WF, Devesa SS, Young HA, Levine PL. Trends in inflammatory breast carcinoma incidence and survival: the surveillance and epidemiology and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–75.PubMedCrossRefGoogle Scholar
  8. 8.
    National Comprehensive Cancer Network. Breast cancer. NCCN clinical practice guidelines in oncology. 2011; v.2. Available at: Accessed July 2011.
  9. 9.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010.Google Scholar
  10. 10.
    Brooks HL, Mandava N, Pizzi WF, Shah S. Inflammatory breast carcinoma: a community hospital experience. J Am Coll Surg. 1998;186:622–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Galmarini CM, Garbovesky C, Galmarini D, Galmarini FC. Clinical outcome and prognosis of patients with inflammatory breast cancer. Am J Clin Oncol. 2002;25:172–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Smooth RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, et al. A single-center experience with inflammatory breast cancer, 1985–2003. Arch Surg. 2006;141:567–73.CrossRefGoogle Scholar
  13. 13.
    Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23:1941–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Mvere MZ, James JJ, Cornford EJ, Tannant SL, Evans AJ, Ellis IO, et al. Frequency and patterns of metastatic disease in locally advanced inflammatory and non-inflammatory breast cancer. Clin Oncol (R Coll Radiol). 2011;23:608–12.CrossRefGoogle Scholar
  15. 15.
    Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, González AM, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50:231–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010;116 Suppl 11:2821–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Sutherland S, Ashley S, Walsh G, Smith IE, Johnston SRD. Inflammatory breast cancer – The Royal Marsden Hospital experience. Cancer. 2010;116 Suppl 11:2815–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Baldini E, Gardin G, Evangelista G, Prochilo T, Collecchi P, Lionetto R. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5:358–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Goldfarb JM, Pippen JE. Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas. Proc (Bayl Univ Med Cent). 2011;24:86–8.Google Scholar
  21. 21.
    Harris E, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Liaw SL, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer. 2004;100:920–8.CrossRefGoogle Scholar
  23. 23.
    Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Rusell CA, Royce ME, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011;29:1014–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Cristofanilli M, Valero V, Buzdar AU, Broglio KR, González-Angulo AM, Sneige N, et al. Inflammatory breast cancer and patterns of recurrence. Cancer. 2007;110:1436–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Cristofanilli M, González-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor-negative in inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Costa SD, Loibl S, Kaufmann M, Zahm DM, Huober J, Eidthmann H, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2010;28:83–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Low JA, Berman AW, Steinberg SM, Danforth DM, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, et al. Incidence and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010;21:2348–55.PubMedCrossRefGoogle Scholar
  31. 31.
    González-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23:7098–104.PubMedCrossRefGoogle Scholar
  32. 32.
    Hennessy BT, González-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Bertucci F, Tarpin C, Charaf-Jauffred E, Bardou VJ, Braud AC, Tallet A, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004;33:913–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Clemons M, Hamilton T, Mansi J, Lockwood G, Goss P. Management of recurrent locoregional breast cancer: oncologist survey. Breast. 2003;12:328–37.PubMedCrossRefGoogle Scholar
  35. 35.
    Friedel G, Kuipers T, Engel C, Schopf C, Veit S, Zoller J, et al. Full-thickness chest wall resection for locally recurrent breast cancer. Thorac Surg Sci 2005;2:Doc01.Google Scholar
  36. 36.
    Feyerabend T, Wiedemann GJ, Jäger B, Vesely H, Mahlmann B, Richter E. Local hyperthermia, radiation and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. Int J Radiat Oncol Biol Phys. 2001;49:1317–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Wilson RE. Surgical management of locally advanced and recurrent breast cancer. Cancer. 1984;53:752–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Veronesi G, Scanagatta P, Goldhirsch A, Rietjens M, Colleoni M, Pelosi G, et al. Results of chest wall resection for recurrent or locally advanced breast malignancies. Breast. 2007;16:297–302.PubMedCrossRefGoogle Scholar
  39. 39.
    Müller AC, Eckert F, Heinrich V, Bamberg M, Brucker S, Hehr T. Re-surgery and chest wall re-irradiation for recurrent breast cancer- a second curative approach. BMC Cancer. 2011;11:197–204.PubMedCrossRefGoogle Scholar
  40. 40.
    Hehr T, Lamprecht U, Glocker S, Clasen J, Paulsen F, Budach W, et al. Thermoradiotherapy for locally recurrent breast cancer with skin involvement. Int J Hyperthermia. 2001;17:291–301.PubMedCrossRefGoogle Scholar
  41. 41.
    Welz S, Hehr T, Lamprecht U, Scheithauer H, Budach W, Bamberg M. Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection. Int J Hyperthermia. 2005;21:159–67.PubMedCrossRefGoogle Scholar
  42. 42.
    Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167:913–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8:398–410.PubMedCrossRefGoogle Scholar
  44. 44.
    Gril B, Evans L, Palmieri D, Steeg PS. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer. 2010;46:1204–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Arslan UY, Oksuzoglu B, Aksoy S, Harputlouglu H, Turker I, Ozisik Y, et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast. 2011;20:562–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J. 2010;16:252–63.PubMedCrossRefGoogle Scholar
  47. 47.
    González-Angulo AM, Morales-Vázquez F, Hortobagyi GN. Overview of the resistance to the systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.PubMedCrossRefGoogle Scholar
  48. 48.
    Moreno-Aspitia A, Pérez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009;84:533–45.PubMedCrossRefGoogle Scholar
  49. 49.
    Rivera E. Management of metastatic breast cancer. Monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol. 2010;33:176–85.PubMedGoogle Scholar
  50. 50.
    O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.PubMedCrossRefGoogle Scholar
  51. 51.
    Albain KS, Nag SM, Calderillo-Ruíz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Thomas ES, Gómez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2 negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.PubMedCrossRefGoogle Scholar
  56. 56.
    Martin M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219–25.PubMedCrossRefGoogle Scholar
  57. 57.
    Chan S, Romieu G, Huober J, Dolozier T, Tubiana-Hulin M, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009;27:1753–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Stemmler HJ, diGiogia D, Freier W, Tessen HW, Gitsch G, Jonat W, et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer. 2011;104:1071–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase III open-label randomized study. Lancet. 2011;377:914–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121:121–31.PubMedCrossRefGoogle Scholar
  61. 61.
    Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of Ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256–63.PubMedCrossRefGoogle Scholar
  62. 62.
    Geyer CE, Forster J, Lindquist T, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.PubMedCrossRefGoogle Scholar
  64. 64.
    Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and ­survival of the expanded HER2+ in cohort EGF103009, a phase II study. Lancet Oncol. 2009;10:581–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Ben Hamida A, Labidi IS, Mrad K, Charaffe-Jauffret E, Ben Arab S, Esterni B, et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer. 2008;8:28–35.PubMedCrossRefGoogle Scholar
  66. 66.
    Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18:1021–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–77.PubMedCrossRefGoogle Scholar
  68. 68.
    Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital Phase II Consortium. Oncologist. 2010;15:810–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Yamauchi H, Ueno NT. Targeted therapy in inflammatory breast cancer. Cancer. 2010;116 Suppl 11:2758–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Juan Alberto Serrano-Olvera
    • 1
  • Claudia Arce-Salinas
    • 2
  • David F. Cantu-de Leon
    • 1
  • Luis Alonso Herrera-Montalvo
    • 3
  • Jaime G. de la Garza-Salazar
    • 4
  1. 1.Department of Clinical ResearchInstituto Nacional de Cancerologia-MexicoTlalpan, Mexico CityMexico
  2. 2.Department of Breast TumorInstituto Nacional de Cancerologia-MexicoMexico CityMexico
  3. 3.Department of Biomedic Research in CancerInstituto Nacional de Cancerologia MexicoMexico CityMexico
  4. 4.Department of Clinical InvestigationInstituto Nacional de Cancerologia-MexicoMexico CityMexico

Personalised recommendations